Asundexian

DB19088InvestigationalSmall molecule

Asundexian is under investigation in clinical trial NCT05686070 (A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After...

Formula / weight: C₂₆H₂₁ClF₄N₆O₄ · 592.94 g/mol (avg)
Also known as: 1(2h)-pyridineacetamide, n-(4-(aminocarbonyl)-3-fluorophenyl)-4-(5-chloro-2-(4-(trifluoromethyl)-1h-1,2,3-triazol-1-yl)phenyl)-.alpha.-ethyl-5-methoxy-2-oxo-, (.alpha.s)-

Resolves to

Compound

UNIILA585UM8DECAS2064121-65-7

Structure

InChIKeyXYWIPYBIIRTJMM-IBGZPJMESA-NSMILESCC[C@H](N1C=C(OC)C(=CC1=O)C1=CC(Cl)=CC=C1N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC=C(C(N)=O)C(F)=C1

Targets

P03951F11

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Asundexian, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account